Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Raül Ondoño"'
Autor:
Raimon Puig de la Bellacasa, José I. Borrell, Xavier Batllori, Jordi Teixidó, Oriol Vallcorba, Claudi de Rocafiguera, Raül Ondoño, Iñaki Galve, Cristina Puigjaner, Mercè Font-Bardia
Publikováno v:
Dipòsit Digital de la UB
Universidad de Barcelona
Universidad de Barcelona
Wheland intermediates are usually unstable compounds and only a few have been isolated at very low temperatures. During our work on tyrosine kinase inhibitors, we studied the bromination of 7 in order to obtain a dibromo substituted pyrido[2,3-d]pyri
Autor:
Iñaki, Galve, Raül, Ondoño, Claudi, de Rocafiguera, Raimon, Puig de la Bellacasa, Xavier, Batllori, Cristina, Puigjaner, Mercè, Font-Bardia, Oriol, Vallcorba, Jordi, Teixidó, José I, Borrell
Publikováno v:
Organicbiomolecular chemistry. 18(48)
Wheland intermediates are usually unstable compounds and only a few have been isolated at very low temperatures. During our work on tyrosine kinase inhibitors, we studied the bromination of 7 in order to obtain a dibromo substituted pyrido[2,3-d]pyri
Autor:
Alex Perálvarez-Marín, Ángel Lirio, Roger Estrada-Tejedor, Germana Falcone, Beatrice Cardinali, Claudia Provenzano, Manuel Pérez-Alonso, Raül Ondoño, Carlos Elvira, Elena Álvarez-Marimon, José I. Borrell
Publikováno v:
Computational and Structural Biotechnology Journal
Computational and Structural Biotechnology Journal, Vol 19, Iss, Pp 51-61 (2021)
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Computational and Structural Biotechnology Journal, Vol 19, Iss, Pp 51-61 (2021)
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Graphical abstract
Highlights • Drug design with rational methods, using structure-based methods. • Novel RNA binders based on pyrido[2,3-d]pyrimidin-7-(8H)-ones. • Myotonic Dystrophy type 1 small molecule drug discovery.
Myotonic Dys
Highlights • Drug design with rational methods, using structure-based methods. • Novel RNA binders based on pyrido[2,3-d]pyrimidin-7-(8H)-ones. • Myotonic Dystrophy type 1 small molecule drug discovery.
Myotonic Dys
Autor:
Raul Ondono, Ángel Lirio, Carlos Elvira, Elena Álvarez-Marimon, Claudia Provenzano, Beatrice Cardinali, Manuel Pérez-Alonso, Alex Perálvarez-Marín, José I. Borrell, Germana Falcone, Roger Estrada-Tejedor
Publikováno v:
Computational and Structural Biotechnology Journal, Vol 19, Iss , Pp 51-61 (2021)
Myotonic Dystrophy type 1 (DM1) is an incurable neuromuscular disorder caused by toxic DMPK transcripts that carry CUG repeat expansions in the 3′ untranslated region (3′UTR). The intrinsic complexity and lack of crystallographic data makes nonco
Externí odkaz:
https://doaj.org/article/efbf11350f5644d1ab15cf644e6b5d93